GET DAILY SIGNALSPulmatrix (PULM) Q3 2026 Earnings: Merger Developments Take Center Stage
Key Takeaways
- Pulmatrix (PULM) is expected to report third quarter 2026 results around early November 2026, with a conference call scheduled for November 9, 2026.
- Limited consensus estimates point to a net loss per share of roughly -$2.00 on revenue near $1.53 million, versus a loss of -$0.24 per share in the year-ago quarter.
- Investor attention is likely to center less on financials and more on the proposed merger with Eos SENOLYTIX and related shareholder approvals.
- The company ended the second quarter of 2026 with $2.2 million in cash and cash equivalents and has flagged a going-concern consideration in its filings.
- Pulmatrix's clinical programs, including PUR1900, PUR3100, and PUR1800, are largely paused while the company pursues licensing, monetization, and the pending merger.
Why This Quarter Matters
Pulmatrix is a clinical-stage biopharmaceutical company focused on inhaled therapies built on its proprietary iSPERSE dry powder delivery platform. With no commercial product revenue, its quarterly reports are less about sales growth and more about cash runway, operating discipline, and corporate strategy. The upcoming third quarter 2026 update arrives at a pivotal moment: shareholders recently voted at a special meeting in late October 2026 on proposals tied to the company's planned merger with Eos SENOLYTIX, including a reverse stock split and an increase in authorized shares. Because the company has flagged that its cash may be sufficient only through the anticipated merger close, this report serves as an important checkpoint on both financial health and the path toward completing the transaction.
What the Limited Estimates Suggest
Analyst coverage of PULM is minimal, so consensus figures should be treated with caution. Based on limited estimates, the company is expected to post a loss of roughly -$2.00 per share on revenue near $1.53 million for the third quarter of 2026. In the same period a year earlier, Pulmatrix reported a loss of -$0.24 per share. In its most recent quarter, the second quarter of 2026, the company reported a loss of -$0.29 per share, which came in narrower than a single consensus estimate of -$2.00. Because research and development spending has been reduced to less than $0.1 million per quarter while clinical development is on hold, investors will likely watch general and administrative expenses, the net loss trend, and the remaining cash and cash equivalents balance more closely than revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the third quarter 2026 report, sentiment is shaped primarily by the pending Eos SENOLYTIX merger rather than quarterly fundamentals. Pulmatrix's shares have traded well below their 52-week high, and the stock has historically shown muted or modest moves around recent earnings releases. Key risk factors include the uncertainty around the merger's completion, the outcome of shareholder votes on the reverse split and authorized share increase, and the company's limited cash position. Because the business has paused active clinical development, traders may react more to any merger-related updates, financing news, or changes to the transaction timeline than to the income statement itself.
Forward Outlook and Key Factors to Monitor
Following the third quarter 2026 report, investors should watch several factors closely. The most important is the status of the proposed merger with Eos SENOLYTIX. Any update on closing conditions, regulatory approvals, or the timeline for completing the transaction is likely to drive the stock more than earnings per share.
Second, monitor the company's cash position and any new financing activity. With roughly $2.2 million in cash and cash equivalents at the end of the second quarter of 2026, plus restricted cash tied to the merger, liquidity remains a central concern. Management's commentary on how long the cash runway extends will be important.
Third, watch for developments on the clinical pipeline. PUR1900, an inhaled antifungal being advanced outside the United States by partner Cipla, has been approved to proceed to a Phase 3 trial in India, and Pulmatrix would receive a royalty on potential future ex-U.S. net sales. Progress on PUR3100 and PUR1800, though currently paused, could also influence longer-term sentiment.
Finally, keep an eye on the company's ongoing compliance with Nasdaq listing requirements, including any share-count and authorized-share changes resulting from the merger vote. These structural items can have a direct effect on the stock's valuation and liquidity. From what I see, running a quick check with Tickeron’s AI Trend Prediction Engine can help flag any emerging patterns in the sector ahead of these updates.
Exploring AI Tools for Research
In my own process, I’ve found Tickeron’s AI Screener to be a practical way to filter small-cap biopharma names and compare technical and fundamental signals across the healthcare space. It allows quick scans based on patterns, volatility, and performance metrics, which can add context when following names like Pulmatrix amid corporate events. This kind of tool helps streamline the review of sector trends without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PULM sees its Stochastic Oscillator recovers from oversold territory
On November 04, 2026, the Stochastic Oscillator for PULM moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 68 instances where the indicator left the oversold zone. In 53 of the 68 cases the stock moved higher in the following days. This puts the odds of a move higher at over 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for PULM just turned positive on November 04, 2026. Looking at past instances where PULM's MACD turned positive, the stock continued to rise in 30 of 48 cases over the following month. The odds of a continued upward trend are 62%.
PULM moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where PULM advanced for three days, in 166 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PULM as a result. In 87 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The 10-day moving average for PULM crossed bearishly below the 50-day moving average on October 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PULM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PULM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. PULM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.214) is normal, around the industry mean (2.904). P/E Ratio (-1.273) is within average values for comparable stocks, (-0.738). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.314) among similar stocks. PULM's P/S Ratio (2500.000) is slightly higher than the industry average of (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PULM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals for pulmonary disease
Industry Biotechnology
Advertisement